IRCT20090613002027N12 IRCT 2018-06-01 Mazandaran University of Medical Scienses Efficacy and safety of bupropion in cancer-related fatigue Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial 2018-04-14 anticipated 30 Complete https://irct.ir/trial/30231 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Patients will enter the trial randomly based on the random number table, Blinding description: participants, principle investigator, healthcare providers, data collectors and outcome assessors. 2 Cancer related fatigue. Intervention 1: Intervention group: administration of bupropion (made by Abidi pharmaceuticals) 75 mg once a day (for three days) then 75 mg twice a day till the end of study (six weeks). Intervention 2: Control group: administration of placebo once a day for the first three days then twice a day till the end of study. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information